---
document_datetime: 2023-09-21 21:56:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/neurobloc-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: neurobloc-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.9991443
conversion_datetime: 2025-12-20 10:07:30.476944
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 01 February 2004 please refer to module 8B

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

<!-- image -->

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                   | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Extension of shelf-life as foreseen at time of authorisation                                                                                                                                                                                                                                                                                                                                                            | I/0001               | I                        | 18.05.01                            | 04.07.01                                 |
| Change in specification of medicinal product                                                                                                                                                                                                                                                                                                                                                                            | I/0002               | I                        | 31.05.01                            |                                          |
| This notification relates to a change affecting the Package Leaflet (Annex IIIB) . Linguistic changes that improve the linguistic quality and readability of the Package Leaflet have also been included.                                                                                                                                                                                                               | N/0003               | N                        | 23.05.01                            | 02.07.01 authorised                      |
| Minor change of manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                                                           | I/0004               | I                        | 18.05.01                            |                                          |
| This notification relates to address changes affecting the Labelling and Package Leaflet (Annex IIIB) .                                                                                                                                                                                                                                                                                                                 | N/0005               | N                        | 12.09.01                            | 29.10.01                                 |
| Change in the batch size of finished product                                                                                                                                                                                                                                                                                                                                                                            | I/0006               | I                        | 15.02.02                            | 18.02.02                                 |
| Minor changes in manufacture of the medicinal product                                                                                                                                                                                                                                                                                                                                                                   | I/0007               | I                        | 08.03.02                            | 18.03.02                                 |
| First Annual Reassessment of the benefit/risk. The Community marketing Authorisation remains under exceptional circumstances for the medicinal product.                                                                                                                                                                                                                                                                 | S/0008               | S                        | 24.04.02                            |                                          |
| Change to sections 4.8 'Undesirable effects' and 4.9 'Overdose' of the SPC further to evaluation of PSUR2 covering the period from 1 July 2001 to 31 December 2001. The PL has been updated accordingly.                                                                                                                                                                                                                | II/0009              | II longer                | 18.12.02                            | 07.03.03                                 |
| Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                                                                                                                          | II/0010              | II                       | 21.11.02                            | 26.11.02                                 |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                                                                                                                                                                                                                                                                             | I/0011               | I                        | 08.11.02                            |                                          |
| Minor change of manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                                                           | I/0012-              | I                        | 18.12.02                            | 19.12.02                                 |
| Second Annual Reassessment of benefit/risk. The Community Marketing Authorisation remains under exceptional circumstances.                                                                                                                                                                                                                                                                                              | S/0013               | S                        | 25.04.03                            | 15.07.03                                 |
| Changes to the sections 4.6 'Pregnancy and lactation' and 5.3 'Preclinical Safety Data' of the SPC further to the evaluation of PSUR3 covering the period from 1 January 2002 to 30 June 2002. no                                                                                                                                                                                                                       | II/0014              | II                       | 22.05.03                            | 16.09.03                                 |
| Change to the botulinum toxin type B reference standard, which is used as a control in the size exclusion chromatography and the SDS- PAGE assay                                                                                                                                                                                                                                                                        | I/0015               | I                        | 29.08.03                            |                                          |
| Changes to the sections 4.8 'Undesirable effects' and 5.2 'Pharmacokinetics properties' of the SPC further to the evaluation of PSUR number 4 covering the period from 1 July 2002 to 31 December 2002. In addition, an amendment to section 5.3 'Preclinical Safety Data' is proposed to correctly reflect the conclusions on reproductive toxicity studies already made through variation EMEA/H/C/301/II/14. product | II/0016              | II                       | 20.11.03                            | 29.01.04                                 |
| The Marketing Authorisation Holder (MAH) applied for the addition of an appearance test of the sodium succinate to the raw material specifications for this excipient.                                                                                                                                                                                                                                                  | IB/17                | IB                       | 11.12.03                            |                                          |
| The MAHapplied for the addition of an appearance of solution test to the raw material specifications for sodium succinate. TheMAH also took the opportunity to add Sigma-Aldrich as an additional supplier of this excipient.                                                                                                                                                                                           | IB/18                | IB                       | 11.12.03                            |                                          |

<!-- image -->